Genfit SA · EURONEXT:GNFT
Genfit SA — Investor Presentation (June 2013)
20 slides from Genfit SA's investor presentation, Jun 14, 2013
Slide 1: GENFIT, a Biopharmaceutical Company
GENFIT, a Biopharmaceutical Company New drugs for Cardiometabolic Diseases & Diabetes Complications
Slide 2: Welcome
Welcome UP1 UP2 screening LC-MS - proteomic 2 bioInformatics 5 in vivo facility 4 3 1 cell biology molecular biology biochemistry/ chemistry
Slide 3: GENFIT, Who Are We?
GENFIT, Who Are We? Jean-François MOUNEY (Chairman & CEO, GENFIT)
Slide 4: GENFIT as of Today
GENFIT as of Today At a Glance A Biopharmaceutical Company Founded in 1999 (Lille, France & Cambridge, US) 80 employees (65 scientists) GENFIT’s world-leading expertise Gene regulation and Nuclear Receptor based drug discovery Cardiometabolic diseases obesity, dyslipidemia, prediabetes
Slide 5: A Solid Track Record in Cardiometabolism
A Solid Track Record in Cardiometabolism With Partners and Stand-Alone An history of successful partnerships Exceeded 100M€ revenues for 13 years Pierre Fabre Sanofi-Aventis Servier Solvay Diabetes, Metabolic Diseases Diabetes, Atherosclerosis, Lipid Disorders CNS Obesity Inflammation 8 years of
Slide 6: GENFIT, From 2000 To 2013
GENFIT, From 2000 To 2013 In the early 2000s: GENFIT’s Genomics Expertise for Pharmas Inception of GENFIT in Lille Eurasanté Health Pole Research alliances with Sanofi, Aventis, Merck-Lipha, Targets UCB Pharma, then Solvay/Abbott, Pierre Fabre, Kowa… Strong scientific expertise Nuclear Recep
Slide 7: GENFIT, From 2000 To 2013
GENFIT, From 2000 To 2013 2005: Be Prepared to Fill Pharmas’Pipelines GENFIT finances its own programs of drug discovery Be ready to offer late-stage products Renewal of the Alliances with Pharmas Based on GENFIT’s proposals / innovations New targets, cellular pathways, mechanisms of actio
Slide 8: GENFIT, From 2000 To 2013
GENFIT, From 2000 To 2013 2009: Human Should Drive Research and Innovation GENFIT, leader of consortia for Diabetes and CVD Large cohorts of patients (over 1000 patients) Collaborations with Universities and Hospitals (France, Germany, UK,…) 2009 Key biotech collaborators Naturalpha (clini
Slide 9: GENFIT, From 2000 To 2013
GENFIT, From 2000 To 2013 2012: Engineered to Find Drugs and Treat Patients Co-Research alliance with Sanofi on a risk-sharing basis Strong mutual commitment / Task-shared activity Leverage complementarities / collaborative 2009 2012 exchanges GFT505, GENFIT’s lead drug candidate in Phase II
Slide 10: GENFIT, From 2000 To 2013
GENFIT, From 2000 To 2013 2013: A robust Pipeline 2013 GFT505 dual PPARα/δ–non PPARγ Phase IIB ongoing in NASH NASH CV Prevention TGFTX1 RORγt Hit to Lead Autoimmune diseases (including, among others, IBD) TGFTX3 Reverbα Lead Optimization • Diabetes, NASH, AHF DGFTX1 New Molecules Development
Slide 11: GENFIT's approach for diabetes associated complications
GENFIT’s approach for diabetes associated complications GFT505, a phase IIb drug candidate for NASH
Slide 12: Disease Complications, the Challenges in Diabetes
Disease Complications, the Challenges in Diabetes GFT505, A Therapeutic Solution for Liver and CV Complications Glucose reduction is not OADS sufficient to avoid Type 2 METFORMIN SULFONYLUREAS diabetes complications GLITAZONES DPP-IV … PREDIABETES RISK FACTORS GFT505 Altered glucose metabolism DIAB
Slide 13: NASH, Non-Alcoholic Steato-Hepatitis
NASH, Non-Alcoholic Steato-Hepatitis A severe form of Non-Alcoholic Fatty Liver Disease 25% of the general population 70% in diabetic and obese patients 5-7 % of the general population in western countries 45M people in North America & Europe STEATOSIS 25-30% in diabetic and obese patients HEALTHY S
Slide 14: Scientific Rationale for Developing GFT505 in NASH
Scientific Rationale for Developing GFT505 in NASH A Pluripotent Product Is Needed, GFT505 Can Meet the Need GFT505, New dual PPARα/δ–non PPARγ product Over 450 patients or healthy volunteers treated with GFT505 to date Beneficial properties for NASH & cardiovascular risk reduction Improvemen
Slide 15: GFT505 Development Plan
GFT505 Development Plan Aligned to Register GFT505 Among the 1st Approved Drugs for NASH 2012 2015 “Proof of Safety & Efficacy” 2012-2015 Phase III Package Pivotal Phase IIb COMPLETED 2016 - 2020 “Ready for Phase III” package Pivotal phase IIb in Europe & US 1-year treatment liver biopsy-based trial
Slide 16: Questions les plus fréquemment posées
Questions les plus fréquemment posées GFT505, Développement clinique et Perspectives Pipeline et Business Development Vie Financière Divers ?
Slide 17: Questions les plus fréquemment posées
Questions les plus fréquemment posées GFT505, Développement clinique et Perspectives Pipeline et Business Development Vie Financière Divers ?
Slide 18: Questions les plus fréquemment posées
Questions les plus fréquemment posées GFT505, Développement clinique et Perspectives Pipeline et Business Development Vie Financière Divers ?
Slide 19: Questions les plus fréquemment posées
Questions les plus fréquemment posées GFT505, Développement clinique et Perspectives Pipeline et Business Development Vie Financière Divers ?
Slide 20: Thank you
Thank you www.genfit.com